Eggs as Part of a Healthy Breakfast

Eggs as Part of a Healthy Breakfast: Lack of Association With Heart Disease Risk

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02297464

Enrollment

Registered

2014-11-21

Start date

2014-07-31

Completion date

2018-03-31

Last updated

2018-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Keywords

Risk

Brief summary

Contrary to popular belief, previous studies have demonstrated beneficial effects of whole egg consumption in modifying biomarkers indicative of a greater risk of coronary heart disease (CHD), chronic inflammation, and insulin resistance. The following study is designed to conduct a comprehensive evaluation of consuming an egg-based breakfast compared to an oatmeal-based breakfast on lipid biomarkers, oxidative stress, inflammation, insulin sensitivity, and satiety in young, healthy men and women. The investigators hypothesize that the consumption of 2 eggs per day will not negatively impact plasma lipids in a young, healthy population.

Interventions

OTHEREggs - 2 per day for breakfast

11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.

OTHER1 packet of oatmeal per day

11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 30 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI 18.5-30, willing to consume eggs and oatmeal daily, proficient in English, and with a healthy lipid profile.

Exclusion criteria

* Currently have liver disease, renal disease, diabetes, cancer, history of stroke or heart disease * Currently taking glucose lowering drugs or supplements * Plasma triglycerides \>500 mg/dL, glucose \>126, total cholesterol \>240 * Pregnant, lactating, or have endocrine or metabolic disorders * BMI ≥ 30 * Blood pressure \> 140/90 (average of 3 readings) * Allergies to eggs * Celiac disease or gluten sensitivity

Design outcomes

Primary

Measure	Time frame
Spectrophotometry, NMR and ELISA will assess plasma lipids.	1 year

Secondary

Measure	Time frame
Visual analog scales (VAS) and ELISA assays will assess satiety.	1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026